PerfeRx Optical

PerfeRx is a biotechnology company specializing in the development of drug-eluting contact lenses designed for sustained ophthalmic drug delivery. The company's core technology involves a thin drug-polymer film encapsulated within a hydrogel contact lens, allowing for the continuous release of medication directly to the ocular surface. This platform aims to improve therapeutic outcomes for conditions like glaucoma by eliminating the need for daily eye drops and ensuring consistent dosing. Developed by researchers from Harvard Medical School and Boston Children's Hospital, the technology represents a significant advancement in ocular pharmacology and patient adherence.